2016-05-04T09:03:57-05:00 2015-06-30 ERNST & YOUNG US LLP 370 17TH STREET 3300 DENVER CO 80202 990 2014-07-01 952160097 THE SALK INSTITUTE FOR BIOLOGICAL STUDIES % KIM E WITMER SALK 8584534100 10010 N TORREY PINES ROAD La Jolla CA 920371002 KIM E WITMER SVP & CFO 8584534100 2016-04-29 true KELLEY SIMON P00791436 7209314000 2014 2016-08-17 19:52:53Z ELIZABETH BLACKBURN PHD 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 136701139 false X WWW.SALK.EDU X 1960 CA BASIC RESEARCH IN THE FOLLOWING: MOLECULAR BIOLOGY & GENETICS, NEUROSCIENCE, AND PLANT BIOLOGY. 32 27 1096 154 101374 56675 138079570 106020719 0 0 29322631 13297108 2219101 5947860 169621302 125265687 0 0 0 0 64194555 65119071 0 0 4901231 55571981 50870446 119766536 115989517 49854766 9276170 478180718 484480296 99223939 107461301 378956779 377018995 X INVOLVED IN RESEARCH ACTIVITIES, THE OBJECTIVES OF WHICH ARE THE ADVANCEMENT AND DISSEMINATION OF KNOWLEDGE RELEVANT TO THE HEALTH AND WELLBEING OF MAN. THE OBJECTIVES ARE MET PRIMARILY THROUGH RESEARCH AND ADVANCED INSTRUCTION IN (A) BIOLOGY, (B) THE CAUSE, PREVENTION AND CURE OF DISEASES, AND (C) THE FACTORS AND CIRCUMSTANCES CONDUCIVE TO THE FULFILLMENT OF MAN'S BIOLOGICAL POTENTIAL. false false 98899993 0 0 Some stem cell methods closer to "gold standard" than others - Stem cells, which can develop into any cell type in the body, hold tremendous potential for creating novel regenerative and disease therapeutics. In a collaborative study, researchers at the Salk Institute added critical understanding to the process of generating stem cells. They determined that stem cells produced by moving genetic material from a skin cell into an empty egg cell-rather than genetically manipulating adult cells back into an embryonic state-more closely resemble human embryonic stem cells, considered the "gold standard." The cells created by transferring genetic material have fewer reprogramming issues and fewer alterations in gene expression levels, making them more accurate for basic research and therapeutic studies. The team's findings were published in Nature. [7/2/14] One injection stops diabetes in its tracks - Salk scientists have discovered that a single injection of the protein FGF1 restores blood sugar levels to a healthy range and holds them there for more than two days. Further, sustained treatment also reverses insulin sensitivity, the underlying physiological cause of diabetes, and with no apparent side effects. The study was performed in mice with diet-induced diabetes, the equivalent of type 2 diabetes in humans. Almost 30 million Americans live with this chronic disease, which can cause serious health problems. While type 2 diabetes can be managed-with various levels of success-there is no specific cure. This exciting discovery, published in Nature, could lead to a new generation of safer, more effective diabetes drugs. [7/16/14] New gene discovered that stops the spread of deadly cancer - To metastasize, cancer cells manipulate the molecular anchors, called focal adhesion complexes, which root cells in place. Lung cancer is especially prone to metastasis and Salk scientists have now identified a gene capable of stopping its spread. Building on previous research demonstrating that many lung cancer cases are missing the LKB1 "anti-cancer" gene and therefore spread rapidly, Salk scientists identified a little-known gene called DIXDC1 that manipulates focal adhesion complexes based on instructions from LKB1. When DIXDC1 is turned on, the adhesions grow sticky, anchoring the cells; when DIXDC1 is turned off, the adhesions become smaller, allowing the tumor cells to escape the lungs. This pathway, detailed in Molecular Cell, should provide a new target for cancer therapies. [7/17/14] Salk scientists uncover new clues to repairing an injured spinal cord - In a discovery that could lead to remarkable new therapies for the thousands of Americans with severe spinal cord injuries, researchers at the Salk Institute identified two small proteins that, in combination, may be able to coax damaged nerves to grow and effectively rewire circuits. The results were published in PLOS Biology. The team had previously demonstrated that the protein p45 promotes nerve regeneration in many animals by preventing myelin-the protective coating around nerve fibers-from halting nerve growth. Humans, however, do not have p45. They have a protein called p75 that attaches to myelin when nerves are damaged and actually prevents repair. Using nuclear magnetic resonance (NMR) technology, the team studied the way pairs of the p75 protein attached to myelin and then discovered that the growth-promoting p45 could disrupt this pairing. Their findings suggest that introducing p45 or a similar molecule could prevent the p75 proteins from pairing, thus allowing damaged nerves to regrow. [8/5/14] Genetic signal prevents immune cells from turning against the body - A healthy immune system balances the work of "killer T cells" that attack pathogens and "regulatory T cells" or "Tregs" that halt the attack when the pathogens are gone. When Tregs fail to signal a halt, killer T cells turn on the body, causing inflammation and autoimmune disorders, such as allergies, asthma, rheumatoid arthritis, multiple sclerosis and type 1 diabetes. Research at the Salk Institute has identified a specific gene sequence, called CNS2, on the Foxp3 gene that is solely responsible for the stability of Tregs and immune system balance. As reported in Cell, the discovery could help develop treatments for autoimmune disorders and some cancers. [8/14/14] Dynamic duo takes out the cellular trash - At the Salk Institute, scientists have further elucidated how immune cells called macrophages remove billions of dead cells from the body each day. When these cells malfunction, dead cells and waste products pile up, destroying healthy tissue and leading to autoimmune diseases such as lupus and rheumatoid arthritis. The researchers discovered that two critical receptors on these cells, Mer and Axl, function in very different environments. As detailed in Nature Immunology and eLife, the Salk team found that Mer identifies and removes dead cells from healthy tissue, while Axl operates within inflammatory environments resulting from infection or tissue trauma. Levels of Axl in the blood, in fact, have proven to be an accurate biomarker of inflammation. Understanding how these receptors perform will help researchers design targeted therapeutics for cancers and autoimmune diseases in which receptors are thought to play a role. [9/29/14] Findings point to an "off switch" for drug resistance to cancer - Cancer is notoriously difficult to combat because cancer cells often mutate to become drug-resistant. Pushing the boundaries of bioinformatics-and collaboratively charting more than 80,000 pieces of RNA per cancer cell-scientists at the Salk Institute have learned that slight genetic differences in cells within the same tumor aid mutation. The team also learned that a high percentage of pre-cancerous cells exposed to chemotherapy (paclitaxel) not only survived but also became more drug-tolerant once becoming a tumor. Their findings, reported in PNAS, lay the groundwork for identifying a diversification "switch" that, if turned off, should decrease or prevent drug resistance in cancer cells. [10/20/14] Salk scientists deliver a promising one-two punch for lung cancer - In about 30 percent of non-small cell lung cancer, a mutation in the KRAS gene leads to drug resistance. Salk scientists have identified a drug combination, reported in Science Translational Medicine, which doubles the survival rate of mice with lung cancer and also halts cancer in pancreatic cells. Mutated KRAS works by clinging to cell membranes and recruiting proteins to ramp up cancer growth. Noting that Zometa, a drug used to treat bone disease, also interfered with cell membrane interactions, the Salk team engineered a similar drug and successfully blocked KRAS. Observing this new drug's negative impact on other cellular functions, the researchers turned to rapamycin, used to prevent organ rejection. By combining the two drugs and injecting them into mouse lung tumors, the team shrank the tumors or stopped their growth. The new treatment holds strong potential for patients with KRAS-related cancer. [11/19/14] Salk researchers unveil powerful method to speed cancer drug discovery - Protein interactions, though often fleeting, play critical roles in the development of many diseases, including cancer. Now Salk scientists have developed a highly sensitive method for detecting these protein interactions. They split lucerifase, an enzyme that generates bioluminescence, in half and attached each half to two proteins of interest. Only when the proteins interacted did the lucerifase emit light, thus revealing the interaction. This new approach, called recombinase enhanced bi-molecular luciferase complementation, or ReBiL, was detailed in Cell Reports. To test their discovery, the scientists employed ReBiL to detect for the very first time in living mammalian cells the interaction between the proteins Ube2t and FANCL. These proteins impact a cell's ability to repair DNA damage, a function often disrupted by disease. ReBiL should aid discovery of new protein interactions that might serve as cancer drug targets as well as provide a platform to screen for badly needed new drug candidates that disrupt abnormal protein interactions. [11/20/14] A new dent in HIV-1's armor - As reported in Genes & Development, Salk researchers have identified a protein, Ssu72, which serves as a switch to awaken human immunodeficiency virus (HIV) even after it has lain dormant in cells for years. More than 35 million people worldwide live with this disease and about one million die each year from it. The Salk team made their discovery by first focusing on a protein created by HIV, Tat, which serves as a cellular lookout for the virus, signaling when the environment is favorable for replication. They learned that Ssu72 binds to Tat and then plays a key role not only in initiating replication but also ramping up the process. While other proteins partnering with Tat are vital to normal ce 98899993 true true false true false false false false false true true true false false true false true false false false true false false false true false false false false true true false false false false false true false false false false true false false false false true true false false false true 150 0 true 1096 true true true false false false false true true false false false false X 32 27 false false false false true true true true true false false true true true true true true true true false AL AK AR CA CT GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X KIM E WITMER 8584534100 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 X William R Brody MD PhD President 50.0 0.0 X X 1571435 0 52350 Irwin M Jacobs SM ScD Chair 3.0 0.0 X X 0 0 0 Darlene M Shiley Vice Chair 2.0 0.0 X X 0 0 0 Theodore Waitt Vice Chair 2.0 0.0 X X 0 0 0 Edward Callaway PhD Trustee/Professor 50.0 0.0 X 282402 0 36907 Linda L Chester Trustee 0.5 0.0 X 0 0 0 Frederick J Dotzler Trustee 0.5 0.0 X 0 0 0 Jennifer L Howse PhD Trustee 0.5 0.0 X 0 0 0 Dean Kamen Trustee 0.5 0.0 X 0 0 0 Benjamin H Lewis Trustee 0.5 0.0 X 0 0 0 Corinne Mentzelopoulos Trustee 0.5 0.0 X 0 0 0 Howard H Newman PhD Trustee 2.0 0.0 X 0 0 0 Ralph S O'Connor Trustee 0.5 0.0 X 0 0 0 Gerald L Parsky Trustee 0.5 0.0 X 0 0 0 Frederik Paulsen PhD Trustee 0.5 0.0 X 0 0 0 Caryl Philips Trustee 0.5 0.0 X 0 0 0 Ernest S Rady Trustee 0.5 0.0 X 0 0 0 Faye Hunter Trustee 0.5 0.0 X 0 0 0 Mary Jane Salk Trustee 0.5 0.0 X 0 0 0 Benjamin S Schapiro Trustee 0.5 0.0 X 0 0 0 Carla J Shatz PhD Trustee/Non Resident Fellow 0.5 0.0 X 0 0 0 Jerre L Stead Trustee 2.0 0.0 X 0 0 0 David F Hale Trustee 0.5 0.0 X 0 0 0 Harvey P White Trustee 0.5 0.0 X 0 0 0 Marna C Whittington PhD Trustee 0.5 0.0 X 0 0 0 M Faye Wilson Trustee 0.5 0.0 X 0 0 0 Daniel C Lewis Trustee 0.5 0.0 X 0 0 0 Sanjay K Jha PhD Trustee 0.5 0.0 X 0 0 0 Greg Lemke PhD Trustee/Professor 50.0 0.0 X 230093 0 27314 Elizabeth Keadle Trustee 0.5 0.0 X 0 0 0 Alan D Gold Trustee 0.5 0.0 X 0 0 0 Beverly Emerson Ph D Trustee/Professor 50.0 0.0 X 204707 0 24861 Donald L Cohn Trustee 0.5 0.0 X 0 0 0 Richard A Heyman Trustee 0.5 0.0 X 0 0 0 Thomas M Jessell PhD Trustee 0.5 0.0 X 0 0 0 Christopher Kintner PhD Trustee/Professor 50.0 0.0 X 208894 0 31808 Marsha A Chandler PhD Exec. Vice Pres/COO 50.0 0.0 X 460665 0 26978 Julia A Miller JD Secretary/Gen. Counsel 50.0 0.0 X 257626 0 38793 Kim E Witmer Treasurer/Sr. VP/CFO 50.0 0.0 X 355170 0 38793 Fred H Gage PhD Professor 50.0 0.0 X 336347 0 35683 Rebecca R Newman VP, External Relations 50.0 0.0 X 335122 0 26978 Inder Verma PhD Professor 50.0 0.0 X 394684 0 35683 Anthony Hunter Ph D Professor 50.0 0.0 X 322207 0 38793 Dennis O'Leary PhD Professor 50.0 0.0 X 329398 0 38793 5288750 0 453734 86 false true false UC REGENTS SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 TRNG PROGRAM/SUBCONT 1998151 SECURITAS SECURITY SERVICE FILE 57220 LOS ANGELES CA 90074 SECURITY 531078 BARNEY BARNEY LLC 9665 GRANITE RIDGE DR SUITE 600 SAN DIEGO CA 92123 INSURANCE BROKER 436212 COOLEY LLP 101 CALIFORNIA STREET5TH FLOOR SAN FRANCISCO CA 941115800 LEGAL 604363 KLARQUIST SPARKMAN LLP 121 SW SALMON STREEET PORTLAND OR 972042988 LEGAL 465410 9 749485 49187327 56083907 3842836 106020719 0 2774082 2774082 0 5797914 5797914 0 0 0 21701748 11178722 10523026 10523026 10523026 119730 749485 256730 -137000 -137000 0 0 ENERGY REBATE 900099 179409 179409 OIL ROYALTIES 900099 4629 4629 UBI(K-1 FLOW THROUGH INCOME) 900099 101374 101374 1534 1534 286946 125265687 101374 19143594 0 0 0 0 3848795 1046987 2477051 324757 0 47584043 41760600 3891341 1932102 3484029 2921445 385467 177117 6716179 5749669 743067 223443 3486025 2923118 385688 177219 402418 75000 327418 241347 171412 69935 187454 187454 0 0 291073 291073 8684052 7365044 599445 719563 40815 11608 4069 25138 1218451 409212 351309 457930 2193317 1651523 413534 128260 0 7160304 5785890 1212343 162071 895094 748804 28172 118118 0 1168867 849238 95672 223957 15037 15037 0 11882641 11139137 518376 225128 143086 143086 SCIENTIFIC SUBCONTRACTS 2926113 2926113 RESEARCH SUPPLIES 12873062 12873062 REPAIRS & PARTS 343162 337195 4550 1417 UBI TAXES 250 250 203903 154936 43956 5011 115989517 98899993 12188293 4901231 14932933 4073248 0 0 46769371 41780446 1015006 602635 103125 132500 0 0 1632492 2269000 27920 23605 598613 1310052 222534763 147301320 77406833 75233443 208701092 205296522 119889300 131323032 0 0 0 0 7104033 22435813 478180718 484480296 15680113 21410011 0 0 24723127 26592827 52919544 52862149 0 0 0 0 0 0 0 0 5901155 6596314 99223939 107461301 X 106869135 100070439 104742172 104439060 167345472 172509496 378956779 377018995 478180718 484480296 X 9276170 -10690558 -523396 X false true X true true true X 120830531 141948096 131344685 138079570 106020719 638223601 0 0 120830531 141948096 131344685 138079570 106020719 638223601 29677691 608545910 3483205 4407819 4331506 4920223 8686425 25829178 3701 3701 18981 407374 170454 176715 185573 959097 665015577 0.91509 0.92701 X OTHER INCOME SCHEDULE A, PART II, LINE 10 Description: OIL ROYALTIES 2010: 16,701 2011: 6,794 2012: 2,951 2013: 5,788 2014: 4,629 Description: NOTE RECEIVABLE INTEREST 2010: 2,280 2011: 0 2012: 462 2013: 0 2014: 0 Description: ENERGY REBATE 2010: 0 2011: 400,580 2012: 167,503 2013: 145,516 2014: 179,409 Description: POSTRETIREMENT BENEFITS 2010: 0 2011: 0 2012: 0 2013: 21,588 2014: 0 Description: REVENUE SHARING-HOST VEHICLE CHARGING STATION 2010: 0 2011: 0 2012: 0 2013: 0 2014: 690 Description: RECYCLING/VAN SALE 2010: 0 2011: 0 2012: 0 2013: 2,333 2014: 0 Descriptioin: NET GIFT SHOP SALES 2010: 0 2011: 0 2012: 0 2013: 1,490 2014: 845 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 1920 1920 false OTHER ACTIVITIES PART II-B, LINE 1I PAID MEMBERSHIP DUES TO RESEARCH AND BIOMEDICAL ORGANIZATIONS, A PORTION OF WHICH ARE CONSIDERED LOBBYING. ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES $ 960 NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH $ 960 218629544 5364024 1892814 7186963 218699419 167637178 29641230 27636790 6285654 218629544 126725558 24531449 20361663 3981493 167637177 113493623 18776974 -1376528 4168510 126725559 89420545 12288420 15274598 3489940 113493623 0.01580 0.98420 false false 1153930 1153930 145951673 91232085 54719588 73848212 56069235 17778977 1580948 1580948 75233443 ALTERNATIVE INVESTMENTS 131319918 F STOCKS NOT-PUBLICLY TRADED <5% 3114 C 131323032 2052 DEFERRED RETIREMENT OBLIGATION 6594262 6596314 X 124222266 -10690558 9390407 -1300151 125522417 -256730 -256730 125265687 116246246 256730 256730 115989516 1 1 115989517 ENDOWMENT FUNDS USES PART V, LINE 4 ENDOWMENT INCOME INTENDED TO BE USED FOR AND TO SUPPORT RESEARCH, OPERATIONS, AND LECTURESHIP EXPENSES. RECONCILIATION OF REVENUE PER AUDITED FS WITH REVENUE PER RETURN PART XI, LINE 2D INVESTMENT RETURN IN EXCESS OF AMOUNT DESIGNATED FOR CURRENT OPERATIONS UNDER SPENDING POLICY AND ROUNDING. Reconciliation of Revenue per Audited FS with Revenue per Return PART XI, LINE 4B Fundraising events expenses. Reconciliation of Expenses per Audited Financial Stmts w Expenses per Rtn PART XII, LINE 2D Fundraising events expenses. PART XII, LINE 4B ROUNDING. North America Program Services Attended conference 237105 Europe (Including Iceland and Greenland) Program Services Attended conference 167518 East Asia and the Pacific Program Services Attended conference 25774 Middle East and North Africa Program Services Attended conference 8907 South America Program Services Attended conference 6562 Central America and the Caribbean Program Services Attended conference 3376 South Asia Program Services Attended conference 2641 Europe (Including Iceland and Greenland) Program Services Scientific subcontract 59689 North America Program Services Scientific subcontract 21537 East Asia and the Pacific Program Services Scientific subcontract 8267 Central America and the Caribbean Investments 87723240 88264616 88264616 true false false true true false NO. OF EMPLOYEES IN THE REGION PART I, LINE 3, COLUMN (C) SCIENTISTS TRAVEL TO FOREIGN COUNTRIES TO ATTEND CONFERENCES. WE DO NOT DEEM THESE ACTIVITIES TO CONSTITUTE WORKING IN THE REGION. ACCOUNTING METHOD PART I, LINE 3, COLUMN (F) ACCRUAL METHOD CONCERT 801608 724985 76623 100966 135000 SCIENCE/MUSIC 67607 24500 43107 3364 17400 0 0 0 0 0 0 0 0 0 0 869215 749485 119730 0 0 0 104330 152400 0 256730 -137000 X X true true X X X X X X false true false false false false false false false William R Brody MD PhD President 690300 0 0 0 881135 0 42667 0 9683 0 1623785 0 717075 0 Edward Callaway PhD Trustee/Professor 236416 0 0 0 45986 0 24114 0 12793 0 319309 0 0 0 Marsha A Chandler PhD Exec. Vice Pres/COO 449997 0 0 0 10668 0 26000 0 978 0 487643 0 0 0 Julia A Miller JD Secretary/Gen. Counsel 255277 0 0 0 2349 0 26000 0 12793 0 296419 0 0 0 Kim E Witmer Treasurer/Sr. VP/CFO 348312 0 0 0 6858 0 26000 0 12793 0 393963 0 0 0 Fred H Gage PhD Professor 331342 0 0 0 5005 0 26000 0 9683 0 372030 0 0 0 Rebecca R Newman VP, External Relations 324524 0 0 0 10598 0 26000 0 978 0 362100 0 0 0 Inder Verma PhD Professor 385052 0 0 0 9632 0 26000 0 9683 0 430367 0 0 0 Anthony Hunter Ph D Professor 300854 0 0 0 21353 0 26000 0 12793 0 361000 0 0 0 Dennis O'Leary PhD Professor 285637 0 0 0 43761 0 26000 0 12793 0 368191 0 0 0 Greg Lemke PhD Trustee/Professor 227982 0 0 0 2111 0 22909 0 4405 0 257407 0 0 0 Beverly Emerson Ph D Trustee/Professor 201856 0 0 0 2851 0 20456 0 4405 0 229568 0 0 0 Christopher Kintner PhD Trustee/Professor 199376 0 0 0 9518 0 20456 0 11352 0 240702 0 0 0 QUESTIONS REGARDING COMPENSATION PART I, LINE 1A FIRST-CLASS OR CHARTER TRAVEL: FRED GAGE, PROFESSOR - $6,433; MARSHA CHANDLER, COO - $10,191. NOT TAXABLE - ACCOUNTABLE PLAN. QUESTIONS REGARDING HOUSING ALLOWANCE OR RESIDENCE PART I, LINE 1A A HOUSING ALLOWANCE IS PROVIDED AND REPORTED AS TAXABLE COMPENSATION. 457(F) PLAN PAYOUT PART I, LINE 4B DEFERRED COMPENSATION PLAN (SECTION 457(F)) WAS ESTABLISHED FOR THE PRESIDENT. THE INSTITUTE'S CONTRIBUTION TO THE PLAN AND THE EARNINGS FROM THE CONTRIBUTION BECAME 100% VESTED UPON THE PRESIDENT'S COMPLETION OF 5 YEARS OF SERVICE. THE PLAN BALANCE OF $717,075.10 WAS PAID OUT TO THE PRESIDENT IN MARCH 2014. A CA STATEWIDE COMM DEV AUTHORITY 680164610 130911S92 2005-08-11 25712839 REFUND 03/30/94 ISSUE false false false B COUNTY OF SAN DIEGO 956000934 797391R50 2010-05-27 37207949 REFUND 04/30/00 ISSUE;RENOVATE/EQU false false false C CA STATEWIDE COMM DEV AUTHORITY 680164610 000000000 2014-08-07 31081050 REFUND 08/11/05 ISSUE;RENOVATE/EQU false false false A 8545000 0 25712839 0 0 0 686939 0 0 0 0 0 true false true true B 1230000 0 37207949 0 0 0 523682 0 0 23537429 0 0 2012 true false true true C 0 0 1635117 0 0 0 108784 0 0 1526333 0 0 false true false true A 0 B false false false false 0 true false false true C false false false false 0 true false false true A false false true false false false 0 false 0 false true B false false true false false false 0 false 0 false C false false true false false false 0 false 0 false true A true B true C true PART II, LINE 3, COLUMN C THE 08/07/2014 ISSUE IS FUNDING RENOVATION/EQUIPMENT PROJECTS AS THEY OCCUR AND WILL FUND THE REDEMPTION OF THE 08/11/2005 BONDS ON 07/01/2015. DENNIS O'LEARY PROFESSOR HOME LOAN X 165000 82500 false true true EDWARD CALLAWAY PROFESSOR HOME LOAN X 50000 50000 false true true 132500 X 40 3842836 MARKET VALUE false true false PART I, COLUMN B THE AMOUNT REPORTED IN THIS COLUMN REPRESENTS THE NUMBER OF CONTRIBUTIONS. GOVERNING BODY AND MANAGEMENT FORM 990, PART VI, SECTION A, LINES 1A, 6, 7A, 7B LINE 1A: THE EXECUTIVE COMMITTEE SHALL ADVISE AND AID THE OFFICERS OF THE CORPORATION IN ALL MATTERS CONCERNING ITS INTERESTS, INCLUDING WITHOUT LIMITATION ALL MATTERS RELATING TO COMPENSATION AND BENEFITS, AND SHALL POSSESS AND MAY EXERCISE, DURING THE INTERVALS BETWEEN THE MEETINGS OF THE BOARD OF TRUSTEES, ALL THE POWERS AND AUTHORITY OF THE BOARD OF TRUSTEES IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE CORPORATION, INCLUDING THE POWER TO AUTHORIZE THE CORPORATE SEAL TO BE AFFIXED TO ANY AND ALL DOCUMENTS WHICH MAY REQUIRE THE SAME TO BE AFFIXED THERETO, INSOFAR AS SUCH SEEMS TO THE EXECUTIVE COMMITTEE FOR THE BEST INTERESTS OF THE CORPORATION, IN ALL CASES IN WHICH SPECIFIC DIRECTIONS SHALL NOT HAVE BEEN GIVEN BY THE BOARD OF TRUSTEES, EXCEPT THAT THE EXECUTIVE COMMITTE SHALL HAVE NO POWER TO ADOPT, AMEND, OR REPEAL THE BY-LAWS. LINE 6: MEMBERSHIP OF THE CORPORATION CONSISTS OF THE PERSONS ELECTED TO THE BOARD OF TRUSTEES AND THREE MEMBERS FROM AMONG THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS CHOSEN AND ELECTED ANNUALLY BY THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS. LINE 7a: THE MEMBERS OF THE CORPORATION ELECT THE TRUSTEES. LINE 7b: THE MEMBERS OF THE CORPORATION MAY ALTER, AMEND, OR REPEAL THE BY-LAWS BY VOTE. POLICIES FORM 990, PART VI, SECTION B, LINES 11B, 12C, AND 15A/B LINE 11B: THE FORM 990 IS PREPARED BY THE INSTITUTE, INTERNALLY REVIEWED BY THE SR. DIRECTOR OF FINANCE AND THE CHIEF FINANCIAL OFFICER AND EXTERNALLY REVIEWED BY THE TAX DEPARTMENT OF A PUBLIC ACCOUNTING FIRM. A COPY OF THE PREPARED FORM 990 IS PROVIDED TO ALL BOARD MEMBERS AND THE AUDIT COMMITTEE FOR REVIEW AND DISCUSSION PRIOR TO ELECTRONIC FILING. LINE 12C: ANNUALLY, THE CONFLICT OF INTEREST DISCLOSURE STATEMENT IS SENT OUT FOR COMPLETION BY THE MEMBERS OF THE BOARD OF TRUSTEES, SENIOR MEMBERS OF ADMINISTRATION AND RESEARCHERS. THE DESIGNATED OFFICIAL FOR EACH GROUP REVIEWS THE COMPLETED FORMS AND BRINGS ANY POTENTIAL CONFLICT OF INTEREST TO THE RESPECTIVE COMMITTEES FOR REVIEW. UPON DETERMINATION THAT A CONFLICT OF INTEREST EXISTS, THE FOLLOWING CONDITIONS OR RESTRICTIONS MAY BE IMPOSED: A. MONITORING OF ACTIVITIES GENERATING THE CONFLICT BY ANOTHER MEMBER; B. DISQUALIFICATION FROM PARTICIPATION IN THE ACTIVITIES GIVING RISE TO THE CONFLICT; C. MODIFICATION OF RESPONSIBILITIES TO AVOID CONFLICTS; D. PUBLIC DISCLOSURE OR DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS; E. MODIFICATION OF THE RESEARCH PLAN OR REMOVAL OF THE AFFECTED RESEARCHER FROM THE RESEARCH; F. SEVERANCE OF RELATIONSHIP THAT CREATES ACTUAL OR POTENTIAL CONFLICTS; G. TERMINATION OF EMPLOYMENT. LINE 15A/B:IN 2014, AN INDEPENDENT CONSULTANT RETAINED BY THE SALK INSTITUTE TO ADVISE ON COMPENSATION ISSUES, ANALYZED THE COMPETITIVENESS OF THE BASE SALARY AND TOTAL COMPENSATION (INCLUDING BENEFITS) FOR THE PRESIDENT, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND VICE PRESIDENT OF EXTERNAL RELATIONS. TOTAL COMPENSATION WAS COMPARED TO LIKE ROLES AMONG ORGANIZATIONS PROVIDING SIMILAR SERVICES IN THE RESEARCH INDUSTRY, INCLUDING BOTH FOR-PROFIT AND NOT-FOR-PROFIT ORGANIZATIONS. THE CONSULTANT CONSIDERED THE SIZE AND SCOPE OF OPERATIONS OF THE INCUMBENTS AND THE GUIDELINES ARTICULATED IN THE SALK INSTIUTUTE EXECUTIVE COMPENSATION POLICY. THE CONSULTANT GAVE THE OPINION THAT THE TOTAL 2014 COMPENSATION WAS WELL WITHIN THE REASONABLE RANGE OF COMPETITIVE PRACTICES. NON-BASE PERFORMANCE RECOGNITION AWARDS WERE REQUESTED AND AWARDED IN JANUARY 2015. HUMAN RESOURCES COMPLETED A SIMILAR TOTAL COMPENSATION ANALYSIS FOR THE GENERAL COUNSEL, VP, ACADEMIC AND ADMINISTRATIVE SERVICES AND VP, SCIENTIFIC SERVICES. THE COMPENSATION COMMITTEE WAS PROVIDED MARKET DATA COMPARISON TO LIKE ROLES AMONG ORGANIZATIONS PROVIDING SIMILAR SERVICES IN THE RESEARCH INDUSTRY AND NOT-FOR-PROFIT SECTORS. HUMAN RESOURCES GAVE THE OPINION THAT THE TOTAL COMPENSATION WAS WELL WITHIN THE REASONABLE RANGE OF COMPETITIVE PRACTICES AND IN LINE WITH THE GUIDELINES ARTICULATED IN THE SALK INSTIUTUTE EXECUTIVE COMPENSATION POLICY. NON-BASE PERFORMANCE RECOGNITION AWARDS WERE REQUESTED AND AWARDED IN JANUARY 2015. AN EXECUTIVE COMPENSATION COMMITTEE WAS FORMED IN 2014. THE COMMITTEE'S PURPOSE IS TO ACT ON BEHALF OF THE BOARD OF TRUSTEES TO EVALUATE THE PERFORMANCE OF THE PRESIDENT/CEO; TO DETERMINE ON AN ANNUAL BASIS, APPROPRIATE COMPENSATION FOR THE PRESIDENT/CEO, EXECUTIVE VICE PRESIDENT, VICE PRESIDENTS AND/OR EQUIVALENT PERSONS; AND TO RECOMMEND TO THE BOARD PLANS AND POLICIES PERTINENT TO THE COMPENSATION FOR THESE EXECUTIVES. DOCUMENTATION ON COMPLETION OF ANNUAL GOALS AND ACHIEVEMENTS WAS PRESENTED TO THE EXECUTIVE COMPENSATION COMMITTEE. THE REPORTS FROM THE INDEPENDENT CONSULTANT AND HUMAN RESOURCES WERE REVIEWED BY THE EXECUTIVE COMPENSATION COMMITTEE AND THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES, EXCLUDING PERSONS WITH A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENTS. THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION ACTIONS WERE INCLUDED IN THE MINUTES OF THE EXECUTIVE COMPENSATON COMMITTEE MEETING AND THE EXECUTIVE COMMITTEE MEETING. COPIES OF BOTH REPORTS WERE ATTACHED TO THE MINUTES OF THE MEETING. DISCLOSURE FORM 990, PART VI, SECTION C, LINE 19 UPON REQUEST, THE OFFICE OF THE CHIEF FINANCIAL OFFICER MAKES AVAILABLE TO THE PUBLIC THE INSTITUTE'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY. FINANCIAL STATEMENTS ARE AVAILABLE ON THE SALK WEB SITE. OTHER CHANGES IN NET ASSETS FORM 990, PART XI, LINE 9 POSTRETIREMENT BENEFIT CHANGES OTHER THAN NET PERIODIC BENEFIT COST - ($523,398); ROUNDING - $1. COMPENSATION OF DIRECTORS FORM 990, PART VII, DIRECTORS COMPENSATION THE FOLLOWING INDIVIDUALS WERE COMPENSATED FOR THE FOLLOWING SERVICES AND NOT PAID AS TRUSTEES: EDWARD M. CALLAWAY, PH.D. - PROFESSOR; BEVERLY EMERSON, PH.D. - PROFESSOR; CHRISTOPHER R. KINTNER, PH.D. - PROFESSOR, GREG LEMKE, PH.D. - PROFESSOR. LA JOLLA BIOLOGICAL LABORATORIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 953655649 Research CA 501(C)(3) 11-I NA true SALK INSTITUTE COMMERCIAL SERVICES CORP 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 232159172 MGMT SERVICES PA SALK INSTITUTE C 16 45721 1.00000 true CHARITABLE REMAINDER TRUSTS(4) SUPPORT CA NA TRUST false false false false false false false false false false false false false true true false true false false NONE